Welcome to our dedicated page for Azenta news (Ticker: AZTA), a resource for investors and traders seeking the latest updates and insights on Azenta stock.
Azenta, Inc. (NASDAQ: AZTA) is a global leader in providing advanced life sciences solutions, empowering breakthrough therapies and expediting their market reach. Headquartered in Burlington, MA, Azenta operates across North America, Europe, and Asia, catering to top pharmaceutical, biotech, academic, and healthcare institutions worldwide.
Azenta offers a comprehensive array of reliable cold-chain sample management solutions and genomic services, spanning critical areas such as drug development, clinical research, and advanced cell therapies. The company’s core business is divided into two segments: Life Sciences Products and Life Sciences Services, with the latter being the primary revenue driver.
Recent achievements highlight Azenta's robust financial health and strategic initiatives. In the fourth quarter of fiscal 2023, the company delivered impressive results amidst challenging economic conditions, underscored by robust cost reduction programs and strategic investments in its sales force. This progress translates into a promising outlook for fiscal 2024, with expected organic revenue growth of 5 to 8%, continued margin expansion, and positive free cash flow.
Azenta's commitment to driving long-term shareholder value is evident through its planned $500 million share repurchase initiative for fiscal 2024. This underscores the company's strong balance sheet and ample liquidity, which includes approximately $500 million in available cash for strategic investments.
Key partnerships and expansions further solidify Azenta's industry footprint. The recent opening of a new Genomics Laboratory in Oxford, UK, enhances its reach, providing local researchers with advanced next-generation sequencing technologies and expertise. Additionally, Azenta has been selected by the Crohn's & Colitis Foundation to manage sample services for significant research cohorts, emphasizing its pivotal role in advancing precision medicine.
Azenta’s portfolio showcases industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, Barkey, and B Medical Systems, which deliver essential support and innovation in life sciences research and development.
The company is also noted for its prudent use of non-GAAP financial measures, providing investors with a clear perspective on operational results relative to industry peers. These measures complement traditional GAAP results by adjusting for items like amortization of intangible assets and restructuring charges, offering a more comprehensive view of financial performance.
As Azenta continues to navigate its transformational journey, including a CEO succession plan aimed at sustaining growth and innovation, it remains committed to its mission of accelerating impactful therapies and supporting the global scientific community.
Azenta, Inc. (NASDAQ: AZTA) reported its Q3 2022 financial results, revealing a revenue of $133 million, a 3% increase year-over-year but a 9% decline sequentially. The diluted EPS from continuing operations was ($0.09), a decrease from the prior quarter. Life Sciences Services achieved a 6% year-over-year increase, driven by storage solutions, despite a decline in Life Sciences Products. The company ended the quarter with $2.5 billion in cash, highlighted by acquisitions of Barkey and B Medical Systems. Q4 2022 revenue guidance is set between $131 million and $141 million.
Azenta, Inc. (Nasdaq: AZTA) has announced a definitive agreement to acquire B Medical Systems for approximately €410 million, with potential additional payments of up to €50 million upon performance milestones. This acquisition, expected to close in October 2022, enhances Azenta's cold chain solutions, particularly in vaccine storage and transportation—targeting growing emerging markets. B Medical reported approximately €109 million in revenue in the past twelve months. The deal is anticipated to benefit Azenta's earnings in fiscal years 2023 and 2024.
Azenta, Inc. (Nasdaq: AZTA) will participate in the UBS Genomics 2.0 and MedTech Innovations Summit on August 11, 2022, starting at 4:00 pm PT. The presentation will be available via live webcast on Azenta's investor relations website. A replay will be accessible after the event. Azenta is a global provider of life sciences solutions, focusing on cold-chain sample management and genomic services across drug development and clinical research. The company, previously known as Brooks Automation, changed its name and ticker on December 1.
Azenta, Inc. (Nasdaq: AZTA) reported preliminary third-quarter results for fiscal 2022, ending June 30. The revenue is projected at $133 million, a 3% increase year-over-year, with 6% organic growth after currency adjustments. GAAP diluted EPS is estimated between ($0.13) and ($0.08), primarily due to tax impacts, while non-GAAP diluted EPS is expected between $0.08 and $0.12. The Services segment revenue is projected at $85 million, with 6% growth, whereas the Products segment is at $47 million, reflecting a 3% decrease year-over-year.
Azenta, Inc. (Nasdaq: AZTA) has successfully completed its acquisition of Barkey Holding GmbH, a renowned provider of controlled rate thawing devices for medical and biotech sectors. This strategic move enhances Azenta's cold chain capabilities and broadens its customer base in the growing cell and gene therapy market, which currently serves over 100 clients. The acquisition is expected to provide significant synergies by extending Azenta's service offerings across all development and commercialization phases. As of December 1, 2021, Azenta changed its name and ticker from Brooks Automation, Inc. (Nasdaq: BRKS).
Azenta, Inc. (Nasdaq: AZTA) has announced a definitive agreement to acquire Barkey Holding GmbH, a leading provider of controlled rate thawing devices for the medical industry, for approximately €80 million. The acquisition is expected to close in early July 2022 and will enhance Azenta's cold chain product offerings in the growing cell and gene therapy market. Barkey generated around €17 million in revenue over the past year and will add significant capabilities to Azenta's operations. The acquisition is anticipated to be accretive to non-GAAP earnings immediately and to GAAP earnings within a year.
Azenta, Inc. (Nasdaq: AZTA) will participate in the Jefferies Healthcare Conference in New York City on June 9, 2022, with a presentation scheduled for 3:30 PM ET. The event will be available via live webcast on Azenta's investor relations website, with a replay accessible afterward.
As a provider of life sciences solutions, Azenta focuses on cold-chain sample management and genomic services, aiding drug development and clinical research. The company rebranded from Brooks Automation, Inc. on December 1, 2021.
Azenta, Inc. (Nasdaq: AZTA), a leading provider of life sciences solutions, will participate in the UBS Global Healthcare Conference on May 24, 2022, at 2:45 pm ET. The live presentation can be accessed via the investor relations website. Azenta, previously known as Brooks Automation, provides essential cold-chain sample management and genomic services, supporting drug development and advanced therapies across various sectors.
Azenta, Inc. (Nasdaq: AZTA) reported preliminary Q2 results for the period ended March 31, 2022. Revenue from continuing operations reached $146 million, reflecting a 12% year-over-year increase. Life Sciences Services showed significant growth of 19%, primarily in Sample Repository Solutions and Genomics Services. However, the company posted a diluted EPS from continuing operations of ($0.02), down from $0.04 the previous quarter, and operating losses totaled $5 million. Azenta anticipates Q3 revenue between $140 million to $150 million.
FAQ
What is the current stock price of Azenta (AZTA)?
What is the market cap of Azenta (AZTA)?
What does Azenta, Inc. specialize in?
Where is Azenta headquartered?
What are Azenta's main business segments?
What recent financial achievements has Azenta reported?
What notable partnerships has Azenta recently formed?
How does Azenta support the life sciences industry?
What brands are encompassed within Azenta’s portfolio?
What is Azenta’s strategy for shareholder value?
How does Azenta use non-GAAP financial measures?
Who is involved in Azenta’s CEO succession plan?
